JZP 258

Drug Profile

JZP 258

Alternative Names: JZP-258; Oxybate mixed salt solution – Jazz Pharmaceuticals; Oxybate – Jazz Pharmaceuticals

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Jazz Pharmaceuticals Inc
  • Class Hydroxybutyrates; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cataplexy; Narcolepsy

Most Recent Events

  • 02 Nov 2016 Phase-III clinical trials in Cataplexy and Narcolepsy in Czech Republic and Spain (PO) (EudraCT2016-000426-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top